Medpace Holdings, INC 8-K filings

Medpace Holdings, Inc. announced robust second quarter 2026 financial results, with significant year-over-year growth in revenue, net income, and EBITDA, alongside strong new business awards.

Medpace Holdings, Inc. announced the appointment of Brad W. Hansman as Executive Vice President, Operations, effective June 1, 2026.

Medpace Holdings, Inc. announced key governance changes approved at its 2026 Annual Meeting, including the removal of supermajority voting requirements and enhanced stockholder rights to call special meetings.

Medpace Holdings, Inc. announced robust first quarter 2026 financial results, including a 26.5% increase in revenue, alongside the planned retirement of its President.

Medpace Holdings, Inc. announced robust third-quarter 2025 financial results, with significant revenue and net new business growth, and provided an optimistic full-year 2025 financial guidance.

Medpace Holdings, Inc. announced robust second quarter 2025 financial results with significant revenue and EBITDA growth, alongside a strategic amendment to its credit facility reducing its line of credit to $10 million.

Medpace Holdings' stockholders approved an amendment to the 2016 Incentive Award Plan, primarily extending the expiration date to February 6, 2035, without increasing the number of authorized shares.

Medpace Holdings, Inc. announced its first quarter 2025 financial results, with revenue increasing by 9.3% but net new business awards decreasing by 18.8%.

Medpace Holdings, Inc. has extended the expiration date of its revolving credit facility with PNC Bank to March 31, 2026, through Amendment No. 7 to its Loan Documents.

Medpace Holdings, Inc. announced a 7.7% increase in Q4 2024 revenue and a $600 million increase to its stock repurchase program.

Medpace Holdings, Inc. announced an 8.3% increase in revenue for the third quarter of 2024, reaching $533.3 million, alongside a significant rise in net income and EBITDA.

Medpace Holdings announced a 14.6% increase in revenue for the second quarter of 2024, reaching $528.1 million, alongside significant growth in net income and EBITDA.

Medpace Holdings, Inc. announced the resignation of Ashley M. Keating from its Board of Directors and the appointment of Dr. Dani S. Zander as her replacement, effective July 1, 2024.

Medpace Holdings, Inc. has amended its corporate charter to phase out its classified board of directors, moving towards annual elections for all directors starting in 2025.

Medpace Holdings, Inc. announced a 17.7% increase in revenue for the first quarter of 2024, reaching $511.0 million, alongside significant growth in net income and EBITDA.

Medpace Holdings, Inc. has amended its credit facility with PNC Bank, reducing the line of credit to $10 million and extending the expiration date to March 31, 2025.

Medpace Holdings, Inc. announced a 26.5% increase in revenue for the fourth quarter of 2023, alongside significant growth in net new business awards and backlog.